KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $2.68.

  • Resmed's EPS (Weighted Average and Diluted) rose 1452.99% to $2.68 in Q4 2025 from the same period last year, while for Dec 2025 it was $10.11, marking a year-over-year increase of 1936.25%. This contributed to the annual value of $9.51 for FY2025, which is 3738.06% up from last year.
  • Latest data reveals that Resmed reported EPS (Weighted Average and Diluted) of $2.68 as of Q4 2025, which was up 1452.99% from $2.37 recorded in Q3 2025.
  • In the past 5 years, Resmed's EPS (Weighted Average and Diluted) registered a high of $2.68 during Q4 2025, and its lowest value of -$0.54 during Q1 2021.
  • For the 5-year period, Resmed's EPS (Weighted Average and Diluted) averaged around $1.68, with its median value being $1.54 (2023).
  • As far as peak fluctuations go, Resmed's EPS (Weighted Average and Diluted) plummeted by 14821.43% in 2021, and later surged by 32592.59% in 2022.
  • Quarter analysis of 5 years shows Resmed's EPS (Weighted Average and Diluted) stood at $1.37 in 2021, then increased by 11.68% to $1.53 in 2022, then dropped by 7.19% to $1.42 in 2023, then skyrocketed by 64.79% to $2.34 in 2024, then grew by 14.53% to $2.68 in 2025.
  • Its EPS (Weighted Average and Diluted) was $2.68 in Q4 2025, compared to $2.37 in Q3 2025 and $2.58 in Q2 2025.